Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
- Submitting institution
-
The University of Leeds
- Unit of assessment
- 5 - Biological Sciences
- Output identifier
- UOA5-723
- Type
- D - Journal article
- DOI
-
10.1016/s1470-2045(18)30935-5
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 649
- Volume
- 20
- Issue
- 5
- ISSN
- 1470-2045
- Open access status
- Compliant
- Month of publication
- April
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
23
- Research group(s)
-
-
- Citation count
- 51
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Contribution A: Contribution to the conception and design of the study,Contribution to the organisation of the conduct of the study,Contribution to carrying out the study,Contribution to analysis and interpretation of the study data
Contribution B: Critique the output for important intellectual content
- Non-English
- No
- English abstract
- -